

Managing Clinical Trial visit during Covid19 Pandemic in King's Clinical Research Facility


| Document Detail | | | | |
|-----------------------|--|--|--|--|
| Document type | Standard Operating Procedure | | | |
| Document name | CRF-QA-SOP-14: Managing clinical Trial visit during Covid-19 Pandemic in the King's CRF | | | |
| Document location | Q-Pulse \ CRF Documents | | | |
| Version | 6.0 | | | |
| Effective from | 24th January 2022 | | | |
| Review date | 24 th January 2023 | | | |
| Author | Angelina Twumasi, Quality Assurance Manager | | | |
| Approved by | Elka Giemza, CRF Manager | | | |
| Authorised by | Professor Peter Goadsby, CRF Director | | | |
| Related documents | CRF-ADMG-FRM-12 Reopening studies and mitigation for COVID-19 at the NIHR Kings CRF KCH Policy for swabbing patient/staff with suspected SARS-COV-2 infection http://skingsdoc/pages/home.aspx KCH Infection and Prevention Control Policy COVID-19: infection prevention and control recommendations By PHE -20 April 2021 Infection prevention and control for seasonal respiratory infections in health and care settings (including SARS-CoV-2) for winter 2021 to 2022 - GOV.UK (www.gov.uk) KCH Guidelines for behaviour in clinical areas national requirement Information on where to get the COVID vaccine and booster is available on the NHS website. | | | |
| Keywords | Covid-19, Pandemic, infection, virus, Standard Infection Prevention Control Precautions (SICPs), Aerosol Generating Procedures (AGPsare) | | | |
| Supporting references | See section 6.0 , Section 7.0 | | | |

THE USER OF THIS DOCUMENT IS RESPONSIBLE FOR ENSURING IT IS THE CURRENT VERSION MASTER COPY





Effective Date: 24 January 2022 Review Date: 24 January 2023 CRF-CL-SOP-14 v6



| Date | Change details, since approval | Approved by |
|------------------|---|-------------|
| December 2020 | Minor administrative changes plus addition of document to Related documents section Section 5.17- Addition of 'I am clean ' stickers Section 5.20- Addition of text regarding testing symptomatic subjects Section 5.21- Addition of Yellow Clean Addition of Section 6.4 Change to author | E. Giemza |
| May 2021 | Section 7.1- PPE table replaced with updated PPE table Keywords- Addition of Standard Infection Prevention Control Precautions (SICPs), Aerosol Generating Procedures (AGPsare) Addition to related documents section & section 6.0 Section 5.5- Clarification of PPE to be worn Section 5.6- Clarification of PPE Section 5.22- Addition of text regarding removal of PPE | E. Giemza |
| June 2021 | Section 5.5- Addition of text 'Bare below the elbow' | E. Giemza |
| November 2021 | Section 5.21- Addition of clarification with regards to OMNICROM variant Minor administrative changes Changes in author Section 6.6- Reference to https://www.gov.uk/government/publications/wuhannovel-coronavirus-infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-health-and-care-settings-infection-prevention-and-control-recommendations | E. Giemza |
| December 2021 | Section 4.5, 5.1, 5.3- Reference to completing lateral flow test with a negative test result before attending the CRF/ CTF Section 5.2- Reference to additional visitors accompanying patients/ volunteers Section 4.6, 5.7- Reference to taking patients/ volunteers/ visitors temperatures, swabbing hub Section 5.8- Reference to self-isolation advice. Minor administrative changes. Minor administrative changes made to the authorised v5.0 Update error – version box above was not changed from version 4.0 to version 5.0 in error | E. Giemza |
| January 2022 | Addition to related documents and supporting references Section 6.0, Section 7.2, Section 4.2-Referring to new national requirement of vaccination status for KCH & KCL staff/ vaccination/ / links Section 5.27 & 5.28- Change to self-isolation requirements. | E. Giemza |

| Review History | | | |
|------------------------|---|-------------|--|
| Date | Review details | Approved by | |
| December 2020 | Review of V1.0 by Chifundo Stubbs CRF Research Nurse, as per the review date. Changes made as per 'Change History' and re-issued as v2.0 | E. Giemza | |
| May 2021 | Review of V2.0 by Angelina Twumasi, CRF Quality Assurance Manager, as per the review date. Changes made as per 'Change History' and re-issued as v3.0 | E. Giemza | |
| November 2021 | Review of V3.1 by Angelina Twumasi, CRF Quality Assurance Manager, as per the review date. Changes made as per 'Change History' and re-issued as v4.0 | E. Giemza | |
| December 2021 | Review of V4.0 by Angelina Twumasi, CRF Quality Assurance Manager, as per the review date. Changes made as per 'Change History' and re-issued as v5.0 | E.Giemza | |
| 30 December 2021 | Review of V5.0 by Angelina Twumasi, CRF Quality | E. Giemza | |
| January 2022 | Review of V5.1 by Angelina Twumasi, CRF Quality Assurance Manager, as per the review date. Changes made as per 'Change History' and re-issued as v6.0 | E. Giemza | |

1.0 Background

- 1.1 Covid-19 has placed a considerable pressure on clinical trials performed by and in the NHS particularly at the King's CRF. The NIHR, King's College Hospital and government bodies have published guidance to ensure that best practice is maintained during this time.
- 1.2 The King's college Hospital NHS Trust has a number of policies and guidelines to ensure preparedness for covid-19 outbreak in other to maintain safety of clinical trial patients and staff. The safety and well-being of the trial participant is the primary concern and measures have been put in place of the CRF to mitigate the spread of virus while in the facility.

THE USER OF THIS DOCUMENT IS RESPONSIBLE FOR ENSURING IT IS THE CURRENT VERSION MASTER COPY
Page 3 of 11

Effective Date: 24 January 2022 Review Date: 24 January 2023

CRF-QA-SOP-14 v6

2.0 Purpose

2.1 The purpose of this Standard Operating Procedure (SOP) is to describe the

process of managing clinical trial patients/volunteers during covid-19 pandemic in

the CRF.

3.0 Scope

3.1 This SOP is applicable to all KHP staff who may be involved in the management

of clinical trial patients/volunteers in the CRF during the covid-19 pandemic.

4.0 Responsibilities

4.1 It is the responsibility of the CRF Manager, CRF QA Manager, CRF Research

Nurses, CRF Research Coordinators/ Practitioners and CRF users who may be

involved in the managing of clinical trial patients/volunteers in the CRF during the

covid-19 pandemic to read, understand and adhere to the procedures described in

this SOP.

4.2 It is the responsibility of all KHP and staff to adhere to the national requirement, for

the vast majority of health and social care workers to receive two doses of a

COVID-19 vaccination by 31 March 2022, which our NHS Trust partners have been

enacting for NHS staff, to ensure they comply with the legislation.

As part of complying with these regulations, please also note that any member of

King's College staff or students who, as a result of their role, have direct in person

interactions with patients in the NHS Trusts will need to have received two doses

of a UK-approved Covid-19 Vaccination by 1 April 2022. This means the first

vaccination must be completed by 3rd February.

This requirement would apply in a primary or secondary clinical setting where

colleagues are offering front line clinical service. It also includes colleagues who

are meeting patients as a result of their involvement in clinical trials, research

studies or patient service-based activity, (whether in clinical, King's College

London, Trust spaces or other premises). Please refer to Section 7.2 for more

clarification.

THE USER OF THIS DOCUMENT IS RESPONSIBLE FOR ENSURING IT IS THE CURRENT VERSION

4.3 It is the responsibility of CRF staff and /or user managing the patient/volunteer to check test results (between 8-24 hour turnaround time) to inform the patient, CRF

manager/team and the sponsor

4.4 It is the responsibility of CRF staff to make the necessary referrals (GP if

community based), and document both on the trust EPR and relevant trial

document.

4.5 It is the responsibility of CRF research Nurses/Nurse delegate, or users to be

trained, fit tested and have undergone a personal risk assessment before able to

undertake the procedure.

4.6 It is the responsibility of the CRF research Nurses/ Clinical Trial Coordinator/

Practitioner to ensure that **all** visitors to the CRF have completed a lateral flow test

producing a negative test result, before attendance.

4.7 It is the responsibility of the CRF/ CTF staff managing the front desk to the facilities

to ensure all visitors have their temperature taken.

5.0 Procedure

5.1 Call patients/volunteers 2 days before the visit to confirm that patient/volunteer is

well enough to attend. Advise them that they need to complete a lateral flow test,

with a negative test result, before attending.

5.2 Patients/ volunteers are not permitted to bring another person to their visit unless

the patient/ volunteer lacks capacity to travel in on their own due to a disability.

This must be discussed with Research staff before attending their visit.

5.3 This additional visitor must complete a lateral flow test, with a negative test result,

before attending.

5.4 Collect covid-19 test swab from central command a day before patient/volunteer's

visit. (If required as per protocol)

5.5 Register patient/volunteer on the EPR system and request for covid-19 RNA on

EPR and print labels.

5.6 Provide patient/volunteer with facemask and gel hand wash on arrival.

5.7 Take the patient/ volunteer's temperature, if the temperature shows 37.8 degrees,

the patient/ volunteer/ additional visitor should immediately be taken to the

swabbing hub to perform a PCR test.

5.8 Wear full PPE before undertaking test. (Sleeves should be worn above the elbows,

staff must be bare below the elbow. Disposable gloves (to be put on after washing

your hands), apron, face mask, goggles or visor) Please refer to section 6.0 and

Section 7.0

- 5.9 Wash your hands thoroughly for at least 20 seconds with soap and warm running water to ensure your hands are clean. Put on a pair of disposable gloves
- 5.10 Remove swab stick from the packet and hold it in your hand. Ask patient to open their mouth wide so you can see the back of throat.
- 5.11 Holding the stick in your hand, gently rub the swab over both tonsils and back of throat for 10 seconds, (using a torch may help you do this). Remove the swab from the back of their throat.
- Using the same end of the same swab, gently rub into their nostrils about 1 inch (2.5cm) or until you feel some resistance. Patient/volunteer can do the swab themselves if they wish to do so.
- Rotate the swab for 10-15 seconds and slowly remove it. 5.13
- 5.14 Place the swab into a virus transport medium tube provided and snap off the other end of swab so it fits inside of the tube.
- 5.15 Label the sample with an EPR label printed
- 5.16 Double bag the labelled sample and send sample to the virology department on the second floor for analysis.
- 5.17 Inform the patient of the test result which could be obtained from EPR.
- The affected person should be advised to leave the hospital and self-isolate 5.18 according to Government guidelines
- 5.19 Advise the patient/ volunteer/ visitor to follow the PHE guideline on Track and Trace and wait for further instructions from sponsor when to restart the study if result is positive.
- 5.20 Patients/ volunteer who test negative will be called with an appointment for study visit.
- 5.21 Disinfect (with Clinell wipes) of all supplies and surfaces used immediately after discharge procedure and ensure proper labelling of cleaned surfaces with 'I am clean' stickers.
- Non-clinical staff who use the facility must wear Facemask at all times as per 5.22 trust policy and should wear PPE when accompanying patient to the facility.
- 5.23 Facial mask to be provided at the CRF reception for non-clinical staff who do not have one.
- 5.24 In the event that a patient/ volunteer/ visitor presents as symptomatic or has come into close contact with someone who is symptomatic or confirmed COVID positive, escort the participant to the Testing Hub opposite the Wellcome Foundation Building to perform the procedure.

- 5.25 Ensure that you order a 'yellow clean' through Medirest, after all testing , patient/ volunteer within the swabbing hub
- 5.26 Ensure that disposable gloves and aprons are removed before leaving clinical or laboratory areas and entering non-clinical/laboratory areas.
- 5.27 In the event of contact with symptomatic people, you must self-isolate for at least 5 days, ensure that you return a negative lateral flow test at any time on day 5 of your self-isolation period, and at the start of your day 6.
- 5.28 If you have a positive lateral flow test, you will be required to self-isolate immediately and won't be required to take a confirmatory PCR test unless symptomatic. If you have COVID-19 symptoms, you need to isolate and book a PCR test regardless of any lateral flow test results.

6.0 Related documents & References

- 6.1 KCH policy for swabbing patient/staff with suspected SARS-COV-2 infection http://:kingsdocs/pages/home.aspx.
- 6.2 https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control
- 6.3 CRF-ADMG-FRM-12 Reopening studies and mitigation for COVID-19 at the NIHR Kings CRF
- 6.4 KCH Infection and Prevention Control Policy
- 6.5 COVID-19: infection prevention and control recommendations by PHE 20 April 2021
- 6.6 <u>Infection prevention and control for seasonal respiratory infections in health and care settings</u>
 (including SARS-CoV-2) for winter 2021 to 2022 GOV.UK (www.gov.uk)
- 6.7 KCH Guidelines for behaviour in clinical areas
- 6.8 Link to national requirement
- 6.9 Link to Information on where to get the COVID vaccine and booster is available on the <u>NHS</u> website

7.0 List of Appendices

7.1 Table 1: PPE recommendations by risk pathway- Public Health England

| Low-risk pathway (PPE required for SICPs) ^[A] | | | | | | |
|---|--------------------------|--|---|---|--|--|
| SICPs/PPE (all settings/all patients/individua ls) | Disposa ble gloves | Disposable apron/gown | Face masks | Eye/face protection (visor) | | |
| If contact with blood and/or body fluids is anticipated | Single use | Single-use apron (gown required if risk of spraying/splashi ng) | FRSM Type IIR for direct patient care and surgical mask Type II for extended use ^[A] | Risk assess and use if required for care procedure/tas k where anticipated blood/body fluids spraying/splas hes | | |
| Medium-risk pathway (PPE required by type of transmission/exposure) | | | | | | |
| PPE required by type of transmission/exp osure | Disposabl e gloves | Disposable apron/gown | Face masks | Eye/face protection (visor) | | |
| Droplet/contact PPE for direct patient care <2 metres | Single use | Single-use apron (gown required if risk of spraying/splas hing) | FRSM Type IIR ^[B] | Single-use or reusable ^[D] | | |

Effective Date: 24 January 2022 Review Date: 24 January 2023

CRF-QA-SOP-14 v6

| Airborne PPE (when undertaking or if AGPs are likely) | Single use | Single use apron or gown | FFP3 ^[C] or respirator/ho od for AGPs | Single use or reusable |
|---|------------|--------------------------|--|------------------------|
| When undertaking AGPs on patients/individua ls with no COVID-19 symptoms and no test result | Single use | Single-use gown | FFP3 or hood for AGPs | Single use or reusable |

Standard Infection Prevention Control Precautions (SICPs)

Aerosol Generating Procedure (AGPsare)

- [A] Sessional/extended use of face masks apply across the UK for healthcare workers in any health or other care settings
- [B] FRSM can be worn sessionally if providing care for COVID-19 cohorted patients/individuals
- [C] FFP3 can be worn sessionally (includes eye/face protection) in high risk areas where AGPsare undertaken for COVID-19 cohorted patients/individuals
- [D] Risk assess and use if required for care procedure/task where anticipated blood/body fluids spraying/splashes below single use/reusable
 - 7.2 There is now a national requirement for the vast majority of health and social care workers to receive two doses of a COVID-19 vaccination by 31 March 2022, which our NHS Trust partners have been enacting for NHS staff, to ensure they comply with the legislation. As part of complying with these regulations, please also note that any member of King's College staff or students who, as a result of their role, have direct in person interactions with patients in the NHS Trusts will need to have received two doses of a UK-approved Covid-19 Vaccination by 1 April 2022. This means the first vaccination must be completed by 3rd February.

This requirement would apply in a primary or secondary clinical setting where colleagues are offering front line clinical service. It also includes colleagues who are meeting patients as a result of their involvement in clinical trials, research

studies or patient service-based activity, (whether in clinical, King's College London, Trust spaces or other premises).

Please discuss this with your line manager or HR people partner if you have any concerns or questions. At this time, the requirement would apply to the following staff categories:

- Clinical Academic and Clinical Research staff who ordinarily have honorary contracts/KHP passports and provide front line clinical service.
- Academic, Research or Professional Services staff who are engaged in research studies, who have direct face to-face interactions with patients.
- Clinical Trials staff involved in managing and administering clinical trials, who have direct face-to-face interactions with patients.
- Academic, Research or Professional Services staff who provide patient facing services, who have direct face-to face interactions with patients.

However, please note that this is an evolving situation, and more staff categories.

Effective Date: 24 January 2022 Review Date: 24 January 2023 CRF-QA-SOP-14 v6

8.0 Approval and sign off

Author:
Name: Angelina Twumasi
Position: Quality Assurance Manager
Signature: Date:

Approved by:
Name: Elka Giemza
Position: CRF Manager
Signature: Date:

Authorised by:
Name: Professor Peter Goadsby
Position: CRF Director
Signature: Date:

Effective Date: 24 January 2022 Review Date: 24 January 2023 CRF-QA-SOP-14 v6